1020104-29-3

Upstream product

• 1020104-28-2 (-)-(1-benzyloxycarbamoyl-but-3-(R)-enyl)-carbamic acid tert-butyl ester 
• 106-95-6 allyl bromide 
• 122149-19-3 N-allyl-O-benzylhydroxylamine 
• 170899-08-8 N-(tert-butoxycarbonyl)-D-allylglycine 
• 622-33-3 N-benzyloxyamine 

Downstream Products

• 1020104-31-7 (-)-(1-benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-R-yl)-carbamic acid tert-butyl ester 
• 1345691-77-1 (-)-N-(1-benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-4-(4-chloro-phenoxy)-benzenesulfonamide 
• 1345691-76-0 (-)-(1-benzyloxy-2-oxo-azepan-3-yl)-carbamic acid tert-butyl ester 
• 1020104-34-0 N-(1-benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-4-(4-chloro-phenoxy)-benzenesulfonamide 
• 1345691-66-8 (-)-4-(4-chloro-phenoxy)-N-(1-hydroxy-2-oxo-azepan-3-yl)-benzenesulfonamide 
• 1020104-27-1 (-)-4-(4-chloro-phenoxy)-N-(1-hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-benzenesulfonamide 
• 1345691-72-6 C₂₅H₂₉N₃O₅S₂ 
• 1020105-28-5 C₂₃H₂₉N₃O₅S₂ 
• 1345691-71-5 C₂₂H₂₆ClN₃O₅S₂ 
• 1020104-51-1 4-(4-Chloro-phenoxy)-N-(1-hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-N-[2-(4-methyl-piperazin-1-yl)-ethyl]-benzenesulfonamide 
• 1020104-50-0 4-(4-Chloro-phenoxy)-N-(1-hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-N-(2-piperidin-1-yl-ethyl)-benzenesulfonamide 
• 1020104-47-5 (-)-4-(4-chloro-phenoxy)-N-(1-hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide 
• 1020104-46-4 N-(1-Hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-4-(4-phenyl-piperazin-1-yl)-benzenesulfonamide 
• 1020104-43-1 N-(1-Hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-4-(4-phenyl-piperidin-1-yl)-benzenesulfonamide 

Relevant academic research and scientific papers

Discovery of novel cobactin-t based matrix metalloproteinase inhibitors via a ring closing metathesis strategy

The discovery of potent N-hydroxyl caprolactam matrix metalloproteinase (MMP) inhibitors (6) based on the natural product Cobactin-T (2) is described. The synthetic method, which utilizes the ring closing metathesis reaction, is compatible to provide comp

Synthesis of the reported structure of the naturally occurring siderophore nocardimicin B

A total synthesis of the reported structure of the naturally occurring siderophore nocardimicin B is reported: the synthetic material appears to be diastereomeric with the natural product.

HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS

This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.